Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 1,201–1,300 of 2,576
van der Linden, R. J., Gerritsen, J. S., Liao, M., Widomska, J., Pearse, R. V., White, F. M., Franke, B., Young‐Pearse, T. L., & Poelmans, G. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102316 · Cited by 43
From Soluble A β to Progressive A β Aggregation: Could Prion‐Like Templated Misfolding Play a Role?
Eisele, Y. S. (2013) · Brain Pathology · doi:10.1111/bpa.12049 · Cited by 40
Shrimpton, A. E., Schelper, R. L., Linke, R. P., Hardy, J., Crook, R., Dickson, D. W., Ishizawa, T., & Davis, R. L. (2007) · Neuropathology · doi:10.1111/j.1440-1789.2007.00766.x · Cited by 40
Self-citationUnfolded Protein Response and Macroautophagy in Alzheimer’s, Parkinson’s and Prion Diseases
Milisav, I., Šuput, D., & Ribarič, S. (2015) · Molecules · doi:10.3390/molecules201219865 · Cited by 43
“An increased Aβ42 to Aβ40 ratio has been observed in AD associated mutations in the APP gene [131] and in the PSEN1 gene for preselin1, the catalytic subunit of the γ-secretase complex [132–135].”
BackgroundTransmembrane Substrate Determinants for γ-Secretase Processing of APP CTFβ
Fernandez, M. A., Biette, K. M., Dolios, G., Seth, D., Wang, R., & Wolfe, M. S. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00718 · Cited by 41
Platelet-generated amyloid beta peptides in Alzheimer's disease and glaucoma.
Inyushin, M. Y., Zayas‐Santiago, A., Rojas, L. V., Kucheryavykh, Y. V., & Kucheryavykh, L. Y. (2019) · PubMed · doi:10.14670/hh-18-111 · Cited by 42
“Aβ peptides secreted by platelets are similar to those found in the senile plaques of AD patients (Scheuner et al., 1996).”
BackgroundRaman, S., Brookhouser, N., & Brafman, D. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104788 · Cited by 42
What is the dominant aβ species in human brain tissue? A review
Gregory, G. C., & Halliday, G. M. (2005) · Neurotoxicity Research · doi:10.1007/bf03033774 · Cited by 50
Formation of Toxic Amyloid Fibrils by Amyloid β‐Protein on Ganglioside Clusters
Matsuzaki, K. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/956104 · Cited by 40
“The 10-fold higher amyloidogenic activity of Aβ-(1–42) is in accordance with the facts (1) that genetic mutations in the presenilins causing early-onset AD increase the level of Aβ-(1–42) [54] and (2) that the protein is the major species in diffuse plaques, the earliest stage in the deposition of Aβ [55].”
ResultTDP-43 misexpression causes defects in dendritic growth
Herzog, J. J., Deshpande, M., Shapiro, L., Rodal, A. A., & Paradis, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-15914-4 · Cited by 45
Crook, R., Ellis, R., Shanks, M., Thal, L. J., Perez‐Tur, J., Baker, M., Hutton, M., Haltia, T., Hardy, J., & Galasko, D. (1997) · Annals of Neurology · doi:10.1002/ana.410420121 · Cited by 40
Self-citationAmyloid, Presenilins, and Alzheimer’s Disease
Gassen, G. V., & Annaert, W. (2003) · The Neuroscientist · doi:10.1177/1073858403252227 · Cited by 41
Petanceska, S. S., Seeger, M., Checler, F., & Gandy, S. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741878.x · Cited by 32
“…elucidated; however, it appears that the Ab C-terminus, generated by one or moreg-secretase enzymes, is the major site of action for mutant PS1 (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997; Holcomb et al., 1998; Price and Sisodia, 1998; Wolfe et al., 1999).”
BackgroundVrièze, F. W., Crook, R., Holmans, P., Kehoe, P. G., Owen, M. J., Williams, J. H., Roehl, K., Lahiri, D. K., Shears, S., Booth, J., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00417-6 · Cited by 40
Self-citationPresenilin-1-Dependent Transcriptome Changes
Mirnics, K., Korade, Z., Arion, D., Lazarov, O., Unger, T., Macioce, M., Sabatini, M., Terrano, D., Douglass, K. C., Schor, N. F., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4145-04.2005 · Cited by 41
“…presenilin 1 (PS1) and presenilin 2 (PS2) lead to familial forms of Alzheimer's disease (FAD) (Rogaev et al., 1995; Sherrington et al., 1995) and are characterized by enhanced production of A 42 peptides (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Borchelt et al., 1997).”
BackgroundGandy, S., & Petanceska, S. S. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00031-4 · Cited by 48
Schindler, S. E., & Fagan, A. M. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00142 · Cited by 45
Proximity-dependent protein detection based on enzyme-assisted fluorescence signal amplification
Tan, Y., Guo, Q., Zhao, X., Yang, X., Wang, K., Huang, J. L., & Zhou, Y. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.08.001 · Cited by 39
Structural and mechanistic principles of intramembrane proteolysis – lessons from rhomboids
Stříšovský, K. (2013) · FEBS Journal · doi:10.1111/febs.12199 · Cited by 39
Role of grape seed polyphenols in Alzheimer’s disease neuropathology
Pasinetti, G. M., & Ho, L. (2010) · Nutrition and Dietary Supplements · doi:10.2147/nds.s6898 · Cited by 48
Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease
Li, C., Ebrahimi, A., & Schluesener, H. J. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.09.002 · Cited by 50
Substrate processing in intramembrane proteolysis by γ-secretase – the role of protein dynamics
Langosch, D., & Steiner, H. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0269 · Cited by 42
Amyloid β-peptides 1–40 and 1–42 form oligomers with mixed β-sheets
Baldassarre, M., Baronio, C. M., Morozova‐Roche, L. A., & Barth, A. (2017) · Chemical Science · doi:10.1039/c7sc01743j · Cited by 45
Chen, C., Liu, Y., Zheng, Z., Zhou, G., Ji, X., Wang, H., & He, Z. (2015) · Analytica Chimica Acta · doi:10.1016/j.aca.2015.05.010 · Cited by 39
de la Vega, M. P., Giedraitis, V., Michno, W., Kilander, L., Güner, G., Zielinski, M., Löwenmark, M., Brundin, R., Danfors, T., Söderberg, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc6184 · Cited by 47
Self-citationLahiri, D. K., Ge, Y., Maloney, B., Vrièze, F. W., & Hardy, J. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.11.005 · Cited by 39
Self-citationThe Dying of the Light: Mitochondrial Failure in Alzheimer's Disease
Young-Collier, K. J., McArdle, M., & Bennett, J. P. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-111487 · Cited by 39
“The ratio of A 1-40 to A 1-42 is typically lower in AD subjects and in cell and animal models [27, 28]; this lower ratio is replicated in our AD P2 pellet samples (Fig.”
Plasma biomarkers of Alzheimer's disease
Kawarabayashi, T., & Shoji, M. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3282fc989f · Cited by 44
Overexpression of calsenilin enhances γ-secretase activity
Jo, D., Jang, J., Kim, B.-J., Lundkvist, J., & Jung, Y. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2004.12.078 · Cited by 43
Small, D. H. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.4.817 · Cited by 39
“For example, a number of familial Alzheimer’s disease mutations cause increased Aβ1-42 production [10].”
BackgroundJudge, M., Hornbeck, L., Potter, H., & Padmanabhan, J. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-80 · Cited by 39
“Mutations in APP and presenilin 1 (PS1) are associated with increased generation of Ab and increased pathology development in AD [34].”
BackgroundProtein Clearance Mechanisms of Alpha-Synuclein and Amyloid-Beta in Lewy Body Disorders
Deleidi, M., & Maetzler, W. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/391438 · Cited by 44
“Comparable to LBDs pathophysiology, in AD, only some rare genetic mutations lead to increased APP expression or to changes in Abeta stability or aggregation [79].”
Use of Yeast as a Model System to Investigate Protein Conformational Diseases
Coughlan, C. M., & Brodsky, J. L. (2005) · Molecular Biotechnology · doi:10.1385/mb:30:2:171 · Cited by 44
Elevation of CD69+Monocyte/Macrophages in Patients with Alzheimer's Disease
Kusdra, L., Rempel, H. C., Yaffe, K. S., & Pulliam, L. (2000) · Immunobiology · doi:10.1016/s0171-2985(00)80049-2 · Cited by 39
Rutten, B. P. F., Wirths, O., Van de Berg, W. D. J., Lichtenthaler, S. F., Vehoff, J., Steinbusch, H. W. M., Korr, H., Beyreuther, K., Multhaup, G., Bayer, T. A., et al. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(02)00015-3 · Cited by 40
LeBlanc, A. C., & Goodyer, C. G. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721832.x · Cited by 39
Alzheimer’s Disease: Genes, Pathogenesis and Risk Prediction
Sleegers, K., & van Duijn, C. M. (2001) · Public Health Genomics · doi:10.1159/000064193 · Cited by 38
Coughlan, C. M., & Breen, K. C. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00036-x · Cited by 45
Thaker, U., McDonagh, A. M., Iwatsubo, T., Lendon, C. L., Pickering‐Brown, S. M., & A. Mann, D. M. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00425.x · Cited by 39
Mazzitelli, S., Filipello, F., Rasile, M., Lauranzano, E., Cucuzza, C. S., Tamborini, M., Pozzi, D., Barajon, I., Giorgino, T., Natalello, A., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0381-9 · Cited by 39
Ntsapi, C., Lumkwana, D., Swart, C., du Toit, A., & Loos, B. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.002 · Cited by 43
Martín‐Belmonte, A., Aguado, C., Alfaro‐Ruiz, R., Moreno‐Martínez, A. E., de la Ossa, L., Hernández, J. M., Buisson, A., Shigemoto, R., Fukazawa, Y., & Luján, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072459 · Cited by 40
“The mouse line used for this study (APP/PS1; hemizygote animals) expressed the Mo/Hu APP695swe construct in conjunction with the exon-9-deleted variant of human presenilin 1 (PS1-dE9) [61].”
MethodInsulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
Alves, S. S., da Silva-Júnior, R. M. P., Servilha‐Menezes, G., Homolak, J., Šalković‐Petrišić, M., & Garcia‐Cairasco, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210234 · Cited by 43
Performance Characteristics of Plasma Amyloid-β 40 and 42 Assays
Okereke, O. I., Xia, W., Irizarry, M. C., Sun, X., Qiu, W. Q., Fagan, A. M., Mehta, P. D., Hyman, B. T., Selkoe, D. J., & Grodstein, F. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0948 · Cited by 37
“Cross-sectional reports [3–5] have demonstrated inconsistent associations between plasma Aβ”
BackgroundSelf-citationDavidsson, P., Bogdanović, N., Lannfelt, L., & Blennow, K. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051266 · Cited by 40
Self-citationChinese Presenilin-1 V97L mutation enhanced Aβ42 levels in SH-SY5Y neuroblastoma cells
Fang, B., Jia, L., & Jia, J. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.06.072 · Cited by 40
Aβ production as consequence of cellular death of a human neuroblastoma overexpressing APP
Recuero, M., Serrano, E., Bullido, M. J., & Valdivieso, F. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.06.025 · Cited by 50
Stover, K. R., & Brown, R. E. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.02.044 · Cited by 46
Spotlight on BACE: The secretases as targets for treatment in Alzheimer disease
Dingwall, C. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14402 · Cited by 38
Pure spastic paraparesis associated with a novel presenilin 1 R278K mutation
Assini, A., Terreni, L., Borghi, R., Giliberto, L., Piccini, A., Loqui, D., Fogliarino, S., Forloni, G., & Tabaton, M. (2003) · Neurology · doi:10.1212/01.wnl.0000040252.43269.83 · Cited by 38
Strooper, B. D., & König, G. (2001) · Nature · doi:10.1038/35102656 · Cited by 41
AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia
Barton, K., & Nucifora, G. (2000) · BioEssays · doi:10.1002/(sici)1521-1878(200003)22:3<214::aid-bies2>3.0.co;2-i · Cited by 20
Monogenetic determinants of Alzheimer's disease: APP mutations
Goate, A. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050218 · Cited by 43
Amyloid β Protein in Plasma as a Diagnostic Marker for Alzheimer’s Disease
Iwatsubo, T. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00015-3 · Cited by 37
Carbone, M. G., Pagni, G., Tagliarini, C., Imbimbo, B. P., & Pomara, N. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101420 · Cited by 43
Can insulin signaling pathways be targeted to transport Aβ out of the brain?
Vandal, M., Bourassa, P., & Calon, F. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00114 · Cited by 41
“…all increase the risk of AD (Goate et al., 1991; Rogaev et al., 1995; Sherrington et al., 1995; Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997), while a mutation more recently found to reduce Aβ production was rather associated with reduced AD…”
Singh, B. K., Vatsa, N., Kumar, V., Shekhar, S., Sharma, A., & Jana, N. R. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx295 · Cited by 39
Chen, J., Zhang, S., Wang, W., Sun, H., Zhang, Q., & Liu, X. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00813 · Cited by 37
Plant-derived acetylcholinesterase inhibitory alkaloids for the treatment of Alzheimer's disease
Dall’Acqua, S. (2013) · Botanics Targets and Therapy · doi:10.2147/btat.s17297 · Cited by 61
Sutton, V. R., & Shaffer, L. G. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20000828)93:5<381::aid-ajmg7>3.0.co;2-9 · Cited by 130
Molecular Neurobiology of Alzheimer's Disease (Syndrome?)
Zubenko, G. S. (1997) · Harvard Review of Psychiatry · doi:10.3109/10673229709000303 · Cited by 40
Ringman, J. M. (2005) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988705281878 · Cited by 37
Butterfield, D. A., & Owen, J. B. (2010) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201000070 · Cited by 39
Sondag, C., & Combs, C. K. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03759.x · Cited by 40
“It is well accepted that APP processing and the generation of Ab are significant events that contribute to the formation of the senile plaques in AD (Masters et al. 1985; Citron et al. 1992; Jarrett et al. 1993; Citron et al. 1994; Scheuner et al. 1996).”
BackgroundPlasmin deficiency does not alter endogenous murine amyloid beta levels in mice
Tucker, H. M., Simpson, J. F., Kihiko‐Ehmann, M., Younkin, L. H., McGillis, J. P., Younkin, S. G., Degen, J. L., & Estus, S. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.07.011 · Cited by 38
Self-citationFunctional characterization of novel presenilin-2 variants identified in human breast cancers
To, M. D., Gökgöz, N., Doyle, T. G., Donoviel, D. B., Knight, J. A., George‐Hyslop, P. S., Bernstein, A., & Andrulis, I. L. (2006) · Oncogene · doi:10.1038/sj.onc.1209397 · Cited by 37
“…not affect Ab(42)/Ab(40) ratio FAD-linked mutations in both PS-1 and PS-2 are associated with an increase in production and secretion of the Ab(42) peptide (Scheuner et al., 1996; Citron et al., 1997), a major component of the amyloid plaques deposited in the brains of Alzheimer’s disease patients.”
BackgroundResultAge-related changes in the localization of presenilin-1 in cynomolgus monkey brain
Kimura, N., Nakamura, S., Honda, T., Takashima, A., Nakayama, H., Ono, F., Sakakibara, I., Doi, K., Kawamura, S., & Yoshikawa, Y. (2001) · Brain Research · doi:10.1016/s0006-8993(01)03146-8 · Cited by 40
Wilson, C. A., Doms, R. W., & Lee, V. M. ‐. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10776 · Cited by 38
“…which currently number over 80 point mutations and one exon deletion in PS1 and six point mutations in PS2, impact A production by increasing the ratio of A 42/A 40 both in cell culture and in transgenic mice (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Murayama et al., 1999).”
BackgroundDe Strooper, B., & Karran, E. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00057-w · Cited by 36
“A more direct clue to their role in AD was the fi nding that presenilin missense mutations, when expressed in cell cultures, increased the generation of long, more aggregation-prone A β 42(43) peptides (Scheuner et al, 1996; Duff et al, 1996), but the underlying mechanism remained elusive.”
BackgroundSun, G. G., Wang, C., Mazzarino, R. C., Perez-Corredor, P. A., Davtyan, H., Blurton-Jones, M., Lopera, F., Arboleda-Velasquez, J. F., & Shi, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114982 · Cited by 36
The Amyloid Cascade Hypothesis
Castellani, R. J., Jamshidi, P., Plascencia‐Villa, G., & Perry, G. L. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.10.014 · Cited by 46
Schupf, N., Lee, A., Park, N., Dang, L.-H., Pang, D., Yale, A., Oh, D. K.-T., Krinsky-McHale, S. J., Jenkins, E. C., Luchsinger, J. A., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.020 · Cited by 36
Genetic of Alzheimer's Disease: A Narrative Review Article.
Khanahmadi, M., Farhud, D. D., & Malmir, M. (2015) · PubMed Central · Cited by 56
The common dementias: a pictorial review
Bhogal, P., Mahoney, C., Graeme-Baker, S., Roy, A., Shah, S., Fraioli, F., Cowley, P., & Jäger, H. R. (2013) · European Radiology · doi:10.1007/s00330-013-3005-9 · Cited by 49
Detection and quantification of plasma amyloid-β by selected reaction monitoring mass spectrometry
Kim, J. S., Ahn, H., Cho, S. M., Lee, J. E., Kim, Y. S., & Lee, C. (2014) · Analytica Chimica Acta · doi:10.1016/j.aca.2014.06.024 · Cited by 36
“Most of the Ab measurements have been performed by antibody-based immunoassays, such as enzyme-linked immunosorbent assay (ELISA) [4,7,9–11] and europium immunoassay (EuIA) [5,6,8].”
BackgroundMethodBiological basis for amyloidogenesis in Alzheimer’S disease
Andreeva, T. V., Lukiw, W. J., & Rogaev, E. I. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917020043 · Cited by 36
The vexing complexity of the amyloidogenic pathway
Castro, M., Hadziselimovic, A., & Sanders, C. R. (2019) · Protein Science · doi:10.1002/pro.3606 · Cited by 44
Divergence in the metabolome between natural aging and Alzheimer’s disease
Hunsberger, H. C., Greenwood, B. P., Tolstikov, V., Narain, N. R., Kiebish, M. A., & Denny, C. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-68739-z · Cited by 42
Choi, H. G., Kim, J., Kim, J. H., Kim, E. S., Park, H. Y., Min, K., & Kwon, M. J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01032-5 · Cited by 36
Mitochondrial dysfunction induced by disease relevant AβPP and tau protein mutations
Keil, U., Hauptmann, S., Bonert, A., Scherping, I., Eckert, A., & Müller, W. E. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9206 · Cited by 36
Enhancer function and novel DNA binding protein activity in the near upstream βAPP gene promoter
Querfurth, H. W., Jiang, J. C., Xia, W., & Selkoe, D. J. (1999) · Gene · doi:10.1016/s0378-1119(99)00091-8 · Cited by 38
Self-citationThe molecular pathology of Alzheimer’s disease
Yates, D. M., & McLoughlin, D. M. (2008) · Psychiatry · doi:10.1016/j.mppsy.2007.11.009 · Cited by 45
Problems Associated with Biological Markers of Alzheimer’s Disease
Frey, H. J., Mattila, K. M., Korolainen, M. A., & Pirttilä, T. (2005) · Neurochemical Research · doi:10.1007/s11064-005-8827-7 · Cited by 42
“Increased plasma levels of Ab42 have been reported occasionally in AD patients, particularly in patients with familial AD, in presymptomatic carriers of mutations causing familial AD ( 42 ), in first degree relatives of AD patients, and in some cognitively normal individuals who developed AD in follow-up (43).”
BackgroundN. Demeester, G. B., Baier, G., & Enzinger, C. (2000) · Molecular Membrane Biology · doi:10.1080/09687680010015838 · Cited by 37
Computer Simulations of Alzheimers Amyloid β-Protein Folding and Assembly
Urbanc, B., Cruz, L., Teplow, D. B., & Stanley, E. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025170 · Cited by 42
“Studies of familial forms of AD indeed show that naturally-occurring mutations strongly influence A metabolism and aggregation [5-7].”
BackgroundPhysiologic and Pathologic Events Mediated by Intramembranous and Juxtamembranous Proteolysis
Golde, T. E., & Eckman, C. B. (2003) · Science's STKE · doi:10.1126/stke.2003.172.re4 · Cited by 36
Self-citationTang, Y., Yamada, K., Kanou, Y., Miyazaki, T., Xiong, X., Kambe, F., Murata, Y., Seo, H., & Nabeshima, T. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00158-3 · Cited by 39
Association of Presenilin-1 Polymorphism With Cerebral Amyloid Angiopathy in the Elderly
Yamada, M., Sodeyama, N., Itoh, Y., Suematsu, N., Otomo, E., Matsushita, M., & Mizusawa, H. (1997) · Stroke · doi:10.1161/01.str.28.11.2219 · Cited by 36
Martins, R. N., Taddei, K., Kendall, C. L., Evin, G. M., Bates, K. A., & Harvey, A. R. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00289-5 · Cited by 39
Amyloid β neurotoxicity in the cholinergic but not in the serotonergic phenotype of RN46A cells
Olesen, O. F., Dagø, L., & Mikkelsen, J. D. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00096-5 · Cited by 37
Zhu, M., Gu, F., Shi, J., Hu, J., Hu, Y., & Zhao, Z. Y. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.08.027 · Cited by 36
“PSmutations linked to early onset familial AD can cause alterations in Aβ production similar to those described in the amyloid-cascade hypothesis [23].”
Lu, Y.-S., Riddell, D., Hajós-Korcsok, É., Bales, K., Wood, K. M., Nolan, C. E., Robshaw, A. E., Zhang, L.-M., Leung, L. Y., Becker, S. L., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192625 · Cited by 37
Kuzuya, A., Zoltowska, K. M., Post, K. L., Arimon, M., Li, X., Svirsky, S. E., Maesako, M., Muzikansky, A., Gautam, V., Kovacs, D. M., et al. (2016) · BMC Biology · doi:10.1186/s12915-016-0248-3 · Cited by 40
“Aβ40 [35–37].”
Maximizing the Potential of Plasma Amyloid-Beta as a Diagnostic Biomarker for Alzheimer’s Disease
Oh, E. S., Troncoso, J. C., & Tucker, S. M. F. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8035-0 · Cited by 37
Fatty acids increase presenilin-1 levels and γ-secretase activity in PSwt-1 cells
Liu, Y., Yang, L., Conde-Knape, K., Beher, D., Shearman, M. S., & Shachter, N. S. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400317-jlr200 · Cited by 35
Payne, A. J., Gerdes, B. C., Naumchuk, Y., McCalley, A. E., Kaja, S., & Koulen, P. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.09.001 · Cited by 37
“…have profound effects on amyloid precursor protein (APP) processing by increasing amyloid beta (Aβ) production and shifting cleavage towards higher levels of the neurotoxic peptide Aβ42 (Borchelt et al., 1996; Duff et al., 1996; Sato et al., 2001; Scheuner et al., 1996; Tomita et al., 1997).”
BackgroundSaraiva, A. M., Cardoso, I., Saraiva, M. J., Tauer, K., Pereira, M. D. C., Coelho, M. A. N., Möhwald, H., & Brezesinski, G. (2010) · Macromolecular Bioscience · doi:10.1002/mabi.200900448 · Cited by 45
Suga, K., Tomiyama, T., Mori, H., & Akagawa, K. (2004) · Biochemical Journal · doi:10.1042/bj20040618 · Cited by 37
Gupta, V., Sundaram, R., & Martins, R. N. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt185 · Cited by 35
Potter, H. (1998) · Frontiers in Bioscience · doi:10.2741/a290 · Cited by 35
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.